Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan

Author:

Habib Muhammad Atif1,Soofi Sajid Bashir12ORCID,Hussain Imtiaz1ORCID,Ahmed Imran1,Hussain Zamir3,Tahir Rehman3,Anwar Saeed4,Cousens Simon5,Bhutta Zulfiqar A.16ORCID

Affiliation:

1. Centre of Excellence in Women and Child Health, Aga Khan University, Karachi 74800, Pakistan

2. Department of Pediatrics & Child Health, Aga Khan University, Karachi 74800, Pakistan

3. Trust for Vaccines and Immunization, Karachi 74400, Pakistan

4. Prime Institute of Public Health, Peshawar 25160, Pakistan

5. London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

6. Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

Abstract

The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2. However, the inactivated poliovirus vaccine (IPV) is safer than OPV, as IPV protects against paralytic poliomyelitis without producing adverse reactions. The present study compared mucosal and humoral responses to poliovirus vaccines administered to previously OPV-immunized children to assess the immunity gap in children in areas of high poliovirus transmission. A cluster-randomized trial was implemented in three high-risk districts of Pakistan—Karachi, Kashmore, and Bajaur—from June 2013 to May 2014. This trial was community-oriented and included three arms, focusing on healthy children below five years of age. The study involved the randomization of 387 clusters, of which 360 were included in the final analysis. The control arm (A) received the routine polio program bivalent poliovirus vaccine (bOPV). The second arm (B) received additional interventions, including health camps providing routine vaccinations and preventive maternal and child health services. In addition to the interventions in arm B, the third arm (C) was also provided with IPV. Blood and stool samples were gathered from children to evaluate humoral and intestinal immunity. The highest levels of poliovirus type 1 serum antibodies were observed in Group C (IPV + OPV). The titers for poliovirus type 2 (P2) and poliovirus type 3 (P3) were noticeably higher in those who had received a routine OPV dose than in those who had not across all study groups and visits. Providing an IPV booster after at least two OPV doses could potentially fill immunity gaps in regions where OPV does not show high efficacy. However, IPV only marginally enhances humoral immunity and fails to offer intestinal immunity, which is critical to stop the infection and spread of live poliovirus in populations that have not been exposed before.

Funder

Bill & Melinda Gates Foundation

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference56 articles.

1. (2020, March 30). Cases of Wild Poliovirus by Country and Year. Available online: http://polioeradication.org/wp-content/uploads/2020/01/Weekly-GPEI-Polio-Analyses-wpv-20191231.pdf.

2. Progress Toward Polio Eradication—Worldwide, January 2016–March 2018;Khan;Morb. Mortal. Wkly. Rep.,2018

3. (2023, August 11). Pakistan Polio Eradication Program, Polio in Pakistan. Available online: https://www.endpolio.com.pk/polioin-pakistan.

4. Pakistan Polio Eradication Programme (2023, August 11). Partners and Donors. Available online: https://www.endpolio.com.pk/polioin-pakistan/partners-and-donors.

5. Government of Islamic Republic of Pakistan (2023, August 11). National Emergency Action Plan for Polio Eradication 2013. Available online: https://www.endpolio.com.pk/images/reports/National-Emergency-Action-Plan-2013-(NEAP-2013).pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3